Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

SGLT2 inhibitors are associated with primary prevention of macrovascular and microvascular complications in diabetes mellitus

SGLT2 inhibitors for primary prevention of macrovascular and major microvascular complications in type 2 diabetes: an island-wide cohort study.

Journal of the Royal Society of Medicine

Citation & Authors

J R Soc Med. 2025;118(11):347-357.

Wan-Yin Cheng; Fu-Shun Yen; Yao-Min Hung; James Cheng-Chung Wei; Heng-Jun Lin; Yu-Han Huang; Chih-Cheng Hsu; Chii-Min Hwu

ABSTRACT · RESEARCH SUMMARY

Research summary

This Taiwanese National Health Insurance study included patients with diabetes but no macrovascular or microvascular disease and performed separate matched comparisons with DPP-4 inhibitors, sulfonylureas, and GLP-1 drugs. SGLT2 inhibitor use was associated with fewer coronary heart disease events, heart failure, dialysis, sight-threatening retinopathy, amputations, and deaths. These findings cover multiple outcomes, and residual differences between treatment populations remain a concern.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗